|
|
||||||||||||||
|
|
|||||||||||||||
EVIDENCE BASED PUBLIC HEALTH POLICY AND PRACTICE |
1 Evaluation and Clinical Epidemiology Department, Institut Municipal dAssistència Sanitària (IMAS); Health Services Research Unit, Institut Municipal dInvestigació Mèdica (IMIM-IMAS) Barcelona, Spain
2 Evaluation and Clinical Epidemiology Department, Institut Municipal dAssistència Sanitària (IMAS); Research Unit on Clinical and Molecular Epidemiology of Cancer (IMIM-IMAS), Barcelona, Spain
Correspondence to:
Correspondence to:
Dr X Castells
Health Services Research Unit, Institut Municipal dInvestigació Mèdica (IMIM-IMAS), Passeig Marítim 2529, 08003, Barcelona, Spain; xcastells{at}imas.imim.es
Study objective: To investigate the cumulative false positive recall rate throughout the period of participation in a population based breast cancer screening programme and to examine its association with women related factors.
Design: Analysis of a database to estimate the cumulative false positive recall rate after 10 biennial mammograms in a cohort of women. Cumulative risk after 10 rounds was calculated by projecting forward the information available on the four rounds. Logistic regression was used to evaluate the association between the cumulative risk of false positive recall and women related factors.
Setting: Population based breast cancer screening programme in Barcelona City (Spain).
Participants: 8502 women aged 5069 years who participated in four consecutive screening rounds. Eligible women had received a mammogram in the first screening round between 1 December 1995 and 31 December 1996.
Main results: The false positive recall rate in the first screening for women who entered the screening programme at the age of 5051 years was assessed at 10.6% (95% CI 8.9, 12.3). In the second screening this risk decreased to 3.8% (95% CI 2.7, 4.9) and remained almost constant in subsequent rounds. After 10 mammograms, the cumulative false positive recall rate was estimated at 32.4% (95% CI 29.7, 35.1). The factors associated with a higher cumulative risk of false positive recall were: previous benign breast disease (OR = 8.48; CI 7.39, 9.73), perimenopausal status (OR = 1.62; CI 1.12, 2.34), body mass index above 27.3 (OR = 1.17; CI 1.02, 1.34), and age 5054 years (OR = 1.15; CI 1.00, 1.31).
Conclusions: One third of women could have at least one false positive recall over 10 biennial screens. Women participating in screening programmes should be informed about this risk, especially those with associated factors.
Abbreviations: FNAC, fine needle aspiration cytology; CNB, core needle biopsy; OB, open biopsy; HRT, hormone replacement therapy; BMI, body mass index
Keywords: false positive reactions; breast neoplasm; mammography; mass screening
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |